bioRxivNeurosciencePreprint
CHRFAM7A overexpression in human iPSC-derived Interneurons dysregulates α7-nAChR surface expression and alters response to oligomeric β-amyloid peptide
Maria Llach PouiD, Camille ThibergeiD, Stéphanie PonsiD, Uwe MaskosiD, Isabelle Cloëz-TayaraniiD
Abstract
The 7 neuronal nicotinic receptor (7-nAChR) gene, CHRNA7, is widely expressed within the brain and at the periphery. It plays various important roles in cognition and immune functions. Decreased expression of 7-nAChR has been associated with Alzheimers disease (AD) triggered by the accumulation of the 42-amino acid beta-amyloid peptide (A{beta}1-42). The interactions of this peptide with 7-nAChR may represent a pivotal mechanism that is involved in pathogenesis of AD. The regulation of CHRNA7 is a complex process. Normal function of 7-nAChR in mammalian cells requires the co-expression of chaperone proteins such as RIC3 and NACHO which facilitate the formation of cell surface receptors. In humans, CHRNA7 regulation also involves the specific chimeric CHRFAM7A gene product dup7, which may assemble with 7 subunits and lead to dominant negative regulation of 7-nAChR function. To further elucidate the complex interplay between CHRFAM7A gene product (dup7), 7-nAChRs and A{beta}1-42, we used human induced pluripotent stem cells (iPSC)-derived interneurons (INs). Four iPSC lines were analyzed for the presence of CHRFAM7A copies. Among them, a cell line with a null genotype was selected for the lentiviral overexpression of CHRFAM7A. Our data show that overexpression of CHRFAM7A led to a reduction in the surface detection of 7-nAChR ligand binding sites in iPSC-derived INs. INs expressing the 7-dup7 subunit (7-dup7-INs) exhibited lower levels of RIC3 and NACHO. Upon agonist treatment by nicotine, an up-regulation of 7-nAChR ligand binding sites was observed in 7-dup7-INs as compared to non-transduced INs (7-INs). At low levels of A{beta} treatment, 7-INs displayed a significant reduction in production of reactive oxygen species (ROS), while high levels resulted in a slight increase. In contrast, 7-dup7-INs exhibited lower baseline levels of ROS that remained unaltered by A{beta} treatment. ROS are known to exacerbate AD pathogenesis. We hypothesize that such effects may also be triggered by 7-dup7-INs in the brain of patients. Further investigations are currently undertaken to confirm this hypothesis.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A failure of β-amyloid physiological function due to genetic deletion of α7 nicotinic acetylcholine receptors induces an Alzheimer's disease-like pathology
Maria Rosaria Tropea, Domenica Donatella Li Puma, … Daniela Puzzo·bioRxiv·Jan 5, 2021
- Co-activation of selective nicotinic acetylcholine receptor subtypes is required for neuroprotection against Alzheimers disease
Rahmi Lee, Gayeon Kim, … Seonil Kim·Advanced SciencePeer-reviewed·Sep 27, 2026
- Selective co-activation of α7- and α4β2-nicotinic acetylcholine receptors reverses beta-amyloid-induced synaptic dysfunction
Jessica P. Roberts, Sarah A. Stokoe, … Seonil Kim·Journal of Biological ChemistryPeer-reviewed·Jan 1, 2021
- Impairment of brain function in a mouse model of Alzheimer's disease during the pre-depositing phase: the role of alpha7 nicotinic acetylcholine receptors
Olena Lykhmus, Wen-Yu Tzeng, … Maryna V. Skok·Biomedicine & PharmacotherapyPeer-reviewed·Aug 7, 2024
- Astrocytes mediate the pro-cognitive value of α7nAChRs and of α7nAChR-targeting therapeutics
Yifan Wu, Michaela Tolman, … Thomas Papouin·bioRxiv·Apr 19, 2026
- CHRNA5 links chandelier cells to severity of amyloid pathology in human aging and Alzheimer's Disease
Jonas Rybnicek, Yuxiao Chen, … Evelyn K. Lambe·Translational PsychiatryPeer-reviewed·Feb 8, 2024